Revolutionizing Muscle Health Diagnostics

Empowering healthcare professionals with the Muscle Assessment Test (MAT) to diagnose and treat disorders resulting from low muscle mass and reduced strength, including diagnosing the contribution of low muscle mass to mobility disability (ICD 10 code R54)

About MyoCorps

MyoCorps is at the forefront of muscle health diagnostics, leveraging cutting-edge science to combat disorders of mobility in adults over 60 that results from low muscle mass. Our patented Muscle Assessment Test (MAT) uses the innovative D₃-creatine dilution method to provide accurate, non-invasive muscle mass measurements—ensuring targeted and effective treatments for disorders of strength, performance and mobility.

Why Address Mobility Disability?

Mobility disability is a well-recognized geriatric syndrome (ICD 10 code R54) that affects millions of older adults and leads to reduced independence, chronic diseases, and higher mortality rates. Common features of mobility disability include:

Low muscle mass has been identified as a critical factor underlying these challenges.

Introducing MyoCorps’ Muscle Assessment Test (MAT)

The MAT offers a breakthrough in diagnosing mobility disability resulting from low muscle mass through a simple, non-invasive urine test. It measures muscle mass with unparalleled accuracy, enabling healthcare professionals to:

Identify those patients with mobility disability that is caused by low muscle mass rather than alternative common causes in the geriatric population of the observed symptoms, such as poor balance, neurological problems (e.g., Parkinson’s disease), cognitive impairment, arthritis, poor vision, orthostatic hypotension, anemia, thyroid disease, limitations due to heart failure, peripheral vascular disease, pain, respiratory disease, obesity, fatigue or comorbid burden.
Tailor effective treatment plans, including resistance training, dietary interventions, and pharmacological therapies or further work-up of non-muscle related cause

Healthcare provider identifies a patient with a mobility disability (diagnosed by questionnaire) and orders a MAT. The MAT ‘kit” contains detailed instructions of how to administer the test, collect a urine sample, and send it (via overnight mail) to MyoCorps. MyoCorps will provide a detailed description of the result and confirm if the patient has low muscle mass.

Oral dose

Urine test

Muscle mass analysis

Meet the MasterMinds behind MyoCorps

Get to know the talented MasterMinds of MyoCorps. With a shared passion for health and innovation, they bring the expertise and creativity that drive our mission to help you reach your full potential.

William J. Evans, PhD

Founder, MyoCorps

CEO is an Adjunct Professor of Medicine in the Division of Geriatrics at the Duke University Medical Center and Human Nutrition in the Department of Nutritional Sciences at the University of California, Berkeley. He previously was Vice President and head of the Muscle Metabolism Discovery Unit at GSK. He has served as laboratory director at the Reynolds Institute on Aging at the University of Arkansas for Medical Sciences, the Noll Physiological Research Center at Penn State and as the Chief of the Human Physiology Laboratory at the Human Nutrition Research Center on Aging at Tufts University. With an h-index of 128 and >80,000 citations, he is the author or co-author of more than 350 publications in scientific journals and was the first to describe the geriatric syndrome, sarcopenia.

Marc Hellerstein, MD PhD

Founder, MyoCorps

President and Chairman of the Board, is Professor and Endowed Chair in Human Nutrition at UC Berkeley and Professor of Endocrinology, Metabolism and Nutrition in the Dept. of Medicine at UCSF. His medical training was at Yale with a PhD from MIT. Dr. Hellerstein’s laboratory has invented new methods to measure in vivo intracellular metabolic processes that play a causal role in the pathogenesis or treatment of disease, as biomarkers for drug development and clinical diagnostics. This has resulted in >340 publications; 23 Issued U.S. and 55 Issued International patents, an H-index of 91; I10 index of 297. Dr. Hellerstein co-founded a medical diagnostics and drug development biotech company, KineMed, Inc., in 2001. He has been on the NASA countermeasures advisory board and many editorial boards.

Partner with MyoCorps

Discover how the MAT can transform your practice and patient outcomes. Reach out to learn more about collaboration, research opportunities, and MAT kit distribution.

Latest News

Stay updated with the latest happenings at MyoCorps. From exciting innovations and breakthroughs to company updates and industry insights, this is where you’ll find all the news that matters.

staging
Comments

Behind the Scenes at MyoCorps: Meet the Team

staging
Comments

Top 5 Tips to Maximize Your Performance with MyoCorps

staging
Comments

The Science Behind MyoCorps: How Innovation Drives Results

Our Commitment to Better Aging

At MyoCorps, we aim to redefine the aging experience by empowering individuals to maintain mobility, strength, and independence. Backed by years of scientific research and global patents, we are committed to improving lives through advanced diagnostics and innovative healthcare solutions.